These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 12359744

  • 1. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
    Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ.
    Cancer Res; 2002 Oct 01; 62(19):5405-7. PubMed ID: 12359744
    [Abstract] [Full Text] [Related]

  • 2. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
    Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH.
    Cancer Epidemiol Biomarkers Prev; 2003 Dec 01; 12(12):1486-91. PubMed ID: 14693742
    [Abstract] [Full Text] [Related]

  • 3. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
    Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE.
    Anticancer Res; 2001 Dec 01; 21(5):3425-32. PubMed ID: 11848504
    [Abstract] [Full Text] [Related]

  • 4. COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.
    Narko K, Zweifel B, Trifan O, Ristimäki A, Lane TF, Hla T.
    Prostaglandins Other Lipid Mediat; 2005 May 01; 76(1-4):86-94. PubMed ID: 15967164
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.
    Lanza-Jacoby S, Burd R, Rosato FE, McGuire K, Little J, Nougbilly N, Miller S.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6161-9. PubMed ID: 17062693
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.
    Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ.
    Cancer Res; 2002 Jul 15; 62(14):3956-61. PubMed ID: 12124326
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K, Sakurai K.
    Int J Oncol; 2003 Sep 15; 23(3):665-72. PubMed ID: 12888902
    [Abstract] [Full Text] [Related]

  • 12. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, Liang L, Guo M, Fenton B, Okunieff P, Ding I.
    Am J Clin Oncol; 2003 Aug 15; 26(4):S103-9. PubMed ID: 12902866
    [Abstract] [Full Text] [Related]

  • 13. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression.
    Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M.
    Biochem Biophys Res Commun; 2004 Apr 02; 316(2):421-8. PubMed ID: 15020235
    [Abstract] [Full Text] [Related]

  • 14. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
    Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, Nicotra MR, Natali PG, Zakut VH, Scambia G.
    Gynecol Oncol; 2002 May 02; 85(2):305-10. PubMed ID: 11972392
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
    Wu R, Abramson AL, Shikowitz MJ, Dannenberg AJ, Steinberg BM.
    Clin Cancer Res; 2005 Sep 01; 11(17):6155-61. PubMed ID: 16144915
    [Abstract] [Full Text] [Related]

  • 16. COX-2 and prostanoid receptors: good targets for chemoprevention.
    Kawamori T, Wakabayashi K.
    J Environ Pathol Toxicol Oncol; 2002 Sep 01; 21(2):149-53. PubMed ID: 12086401
    [Abstract] [Full Text] [Related]

  • 17. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
    Suh YJ, Chada S, McKenzie T, Liu Y, Swisher SG, Lucci A, Hunt KK.
    Surgery; 2005 Sep 01; 138(3):422-30. PubMed ID: 16213894
    [Abstract] [Full Text] [Related]

  • 18. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ.
    Clin Cancer Res; 2005 Mar 01; 11(5):1999-2007. PubMed ID: 15756026
    [Abstract] [Full Text] [Related]

  • 19. Celecoxib reduces skin damage after radiation: selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor.
    Liang L, Hu D, Liu W, Williams JP, Okunieff P, Ding I.
    Am J Clin Oncol; 2003 Aug 01; 26(4):S114-21. PubMed ID: 12902868
    [Abstract] [Full Text] [Related]

  • 20. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
    Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM.
    Cancer Res; 1998 Dec 01; 58(23):5500-6. PubMed ID: 9850086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.